Neoadjuvant Chemotherapy Therapy Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
Conditions: Larynx Cancer; Hypopharyngeal Cancer Interventions: Procedure: Surgery; Radiation: Radiation; Drug: Toripalimab Sponsors: Fudan University; Fudan University Eye Ear Nose and Throat Hospital; Shanghai Zhongshan Hospital; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University; Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition: HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions: Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel; Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor: Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
Conditions: Larynx Cancer; Hypopharyngeal Cancer Interventions: Procedure: Surgery; Radiation: Radiation; Drug: Toripalimab Sponsors: Fudan University; Fudan University Eye Ear Nose and Throat Hospital; Shanghai Zhongshan Hospital; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University; Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition: HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions: Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel; Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor: Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
Conditions: Larynx Cancer; Hypopharyngeal Cancer Interventions: Procedure: Surgery; Radiation: Radiation; Drug: Toripalimab Sponsors: Fudan University; Fudan University Eye Ear Nose and Throat Hospital; Shanghai Zhongshan Hospital; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University; Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition: HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions: Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel; Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor: Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
Conditions: Larynx Cancer; Hypopharyngeal Cancer Interventions: Procedure: Surgery; Radiation: Radiation; Drug: Toripalimab Sponsors: Fudan University; Fudan University Eye Ear Nose and Throat Hospital; Shanghai Zhongshan Hospital; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University; Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition: HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions: Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel; Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor: Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
Conditions: Larynx Cancer; Hypopharyngeal Cancer Interventions: Procedure: Surgery; Radiation: Radiation; Drug: Toripalimab Sponsors: Fudan University; Fudan University Eye Ear Nose and Throat Hospital; Shanghai Zhongshan Hospital; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University; Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition: HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions: Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel; Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor: Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
Conditions: Larynx Cancer; Hypopharyngeal Cancer Interventions: Procedure: Surgery; Radiation: Radiation; Drug: Toripalimab Sponsors: Fudan University; Fudan University Eye Ear Nose and Throat Hospital; Shanghai Zhongshan Hospital; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University; Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition: HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions: Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel; Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor: Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer
Conditions: Larynx Cancer; Hypopharyngeal Cancer Interventions: Procedure: Surgery; Radiation: Radiation; Drug: Toripalimab Sponsors: Fudan University; Fudan University Eye Ear Nose and Throat Hospital; Shanghai Zhongshan Hospital; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University; Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Condition: HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions: Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel; Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor: Biocon Biologics UK Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
Condition: Biliary Tract Neoplasms Intervention: Drug: Total Neoadjuvant Treatment Sponsor: The First Affiliated Hospital with Nanjing Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2023 Category: Research Source Type: clinical trials
